Industry committee  Thank you. It's a pleasure to answer that question. You're absolutely right. At the outset of the pandemic, when Canada went looking for the capacity that it could rely on to develop and manufacture a COVID vaccine, it found a sector that had been largely diminishing over many years.

Industry committee  That's a very important question. I'm happy to answer it and to provide as much information as I can regarding the process for making investment decisions and, quite frankly, the situation regarding Canada's investment in Medicago. The first thing I would say is that there is an extensive process for vetting requests for funding under the strategic innovation fund, a significant due diligence that, of course, includes a significant examination of the financial situation of the applicant, including the ownership structure.

Industry committee  Absolutely, and thank you very much for the question. Medicago is most certainly one of the vaccine manufacturers in the country that we've invested in over the last number of years.

Industry committee  Thank you, Chair. Good afternoon, members. On behalf of my colleagues, we're very pleased to be here today to provide you with an update on domestic biomanufacturing capacity in Canada. It's well established that at the outset of the pandemic, Canada had very little of the biomanufacturing capacity required to produce the relevant vaccines.